Ozempic

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Lilly trumpets heart health data with Mounjaro

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

MHRA's chief safety officer, Dr Alison Cave

UK probes link between GLP-1 drugs and pancreatitis

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

News

Novo Nordisk obesity drug linked to rare cause of sight loss

The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.

News

Ozempic patient blinded by NAION sues Novo Nordisk

Novo Nordisk has seen its first lawsuit over the proposed link between Ozempic and the rare eye disorder NAION.

Novo Nordisk weakens again on interim results readout

Lilly trumpets heart health data with Mounjaro

Novo Nordisk slumps as it cuts sales forecast, names new CEO

UK probes link between GLP-1 drugs and pancreatitis

Novo Nordisk obesity drug linked to rare cause of sight loss

Ozempic patient blinded by NAION sues Novo Nordisk

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Ozempic

Editor's Picks